{
    "clinical_study": {
        "@rank": "26905", 
        "arm_group": [
            {
                "arm_group_label": "MEDI7510", 
                "arm_group_type": "Active Comparator", 
                "description": "RSV sF antigen plus adjuvant"
            }, 
            {
                "arm_group_label": "RSV sF", 
                "arm_group_type": "Active Comparator", 
                "description": "antigen"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "sterile saline"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the administration of single ascending\n      intramuscular doses of the RSV sF antigen or MEDI7510 will be safe and well tolerated in\n      adults 60 years or older who are healthy or who have stable, chronic underlying medical\n      conditions."
        }, 
        "brief_title": "A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Syncytial Virus (RSV)", 
        "condition_browse": {
            "mesh_term": "Virus Diseases"
        }, 
        "detailed_description": {
            "textblock": "A phase 1a, first time in human, double-blind, randomized, placebo-controlled, cohort\n      escalation study evaluating the safety and tolerability of a single ascending intramuscular\n      dose of RSV sF or MEDI7510 or placebo.\n\n      Approximately 144 subjects will be enrolled at 3 US study centers and randomized in a 5:1\n      ratio by cohort to receive a single dose of either  RSV sF or placebo or MEDI7510 on Day 1.\n\n      Cohort 1: RSV sF formulation 1 (n=20) or placebo (n=4) Cohort 1a:  MEDI7510 formulation 1\n      (n=20) or placebo (n=4) Cohort 2:  RSV sF (n=20) formulation 2 or placebo (n=4) Cohort 2a:\n      MEDI7510 (n=20) formulation 2 or placebo (n=4) Cohort 3:  RSV sF (n=20) formulation 3 or\n      placebo (n=4) Cohort 3a:  MEDI7510 (n=20) formulation 3 or placebo (n=4)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        :-Age greater than or equal to 60 years\n\n          -  Written informed consent and any locally required authorization obtained prior to any\n             protocol related procedures\n\n          -  Ambulatory or ambulatory with assistance (not institutionalized, bedridden, or\n             homebound\n\n          -  Weight at or above 110 lbs\n\n          -  Hemoglobin within normal range for age and gender -Subject available by telephone\n\n          -  Subject able to understand and comply with the requirements of the protocol, as\n             judged by the investigator\n\n          -  Subject able to complete follow-up period of 360 days after dosing\n\n        Exclusion Criteria:\n\n          -  History of allergy to any component of the vaccine\n\n          -  Pregnancy or potential to become pregnant during the study. Females who have had a\n             menstrual period within the 12 months prior to study enrollment or are undergoing any\n             fertility treatment or who plan to undergo fertility treatments during the study\n             period are excluded\n\n          -  Any unstable chronic medical condition, including one that has resulted in change in\n             therapy (medication or other) in the 30 days prior to randomization or\n             hospitalization in the previous year or might be predicted to result in\n             hospitalization in the year after enrollment. Subjects with severe, untreated or\n             uncontrolled underlying medical disease that might either compromise subject safety\n             or affect the ability to assess safety of the investigational product are excluded\n\n          -  Clinically significant abnormalities in screening laboratory assessments or screening\n             ECG\n\n          -  History of hepatitis B or hepatitis C infection\n\n          -  Cognitive disorder such that informed consent cannot be obtained directly from the\n             subject\n\n          -  Previous vaccination against RSV\n\n          -  History of allergy to eggs in adulthood\n\n          -  History of or current autoimmune disorder\n\n          -  Immunosuppression caused by disease, including HIV, or medications. Any oral\n             prednisone dosing within 30 days of enrollment or planned dosing within the 360-day\n             follow-up period would disqualify.\n\n          -  History of splenectomy or of condition affecting splenic function\n\n          -  History of cancer within preceding 5 years other than treated non-melanoma skin\n             cancer\n\n          -  Body Mass Index 40 or higher\n\n          -  Significant infection or other acute illness, including fever over 100 F on the day\n             prior to or day of randomization\n\n          -  Receipt of any nonstudy vaccine within 30 days prior to study dosing or expected\n             receipt of nonstudy vaccine within 30 days after study dosing\n\n          -  Receipt of any investigational product in the 90 days prior to randomization or\n             expected receipt of investigational product during the period of study follow-up\n\n          -  Receipt of immunoglobulins or blood products within 4 months of study dosing (120\n             days) or expected receipt of investigational product during the period of study\n             follow-up History of thrombocytopenia or bleeding disorder or use of anticoagulants.\n             Subjects receiving drugs with anti-platelet activity such as nonsteroidal\n             antiinflammatory drugs, clopidogrel or aspirin are not excluded\n\n          -  Expected receipt of antipyretic or analgesic medication on a daily or every other day\n             basis from randomization through 72 hours after receipt of IP (a daily dose of 163 mg\n             or higher is not considered a contraindication to enrollment)\n\n          -  Subjects who have significant scarring, tattoos, abrasions, cuts, or infections over\n             the deltoid region of both arms that, in the PI's opinion, could interfere with\n             evaluation of injection site local reactions\n\n          -  Any condition that, in the PI's opinion, would interfere with evaluation of the IP or\n             interpretation of subject safety or study results\n\n          -  Concurrent enrollment in another clinical study that involves any invasive clinical\n             procedure, including phlebotomy\n\n          -  History of alcohol or drug abuse or psychiatric disorder that in the PI's opinion\n             would affect the subject's safety or compliance with study\n\n          -  Employees of individuals directly involved with the conduct of the study, individuals\n             who themselves are involved with the conduct of the study, or immediate family\n             members of such individuals."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115815", 
            "org_study_id": "CD-VA-MEDI7510-1134"
        }, 
        "intervention": [
            {
                "arm_group_label": "MEDI7510", 
                "description": "RSV sF antigen plus adjuvant", 
                "intervention_name": "MEDI7510", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "RSV sF", 
                "description": "antigen", 
                "intervention_name": "RSV sF", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "sterile saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Miami Research Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Compass Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20850"
                    }, 
                    "name": "Accelovance, Inc"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults", 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "Amanda Fleming", 
            "phone": "301-398-5992"
        }, 
        "overall_contact_backup": {
            "last_name": "Kristin Kopasz", 
            "phone": "301-398-5079"
        }, 
        "overall_official": [
            {
                "affiliation": "Miami Research Associates", 
                "last_name": "Eric Sheldon, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Compass Research", 
                "last_name": "Craig Curtis, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Accelovance Inc.", 
                "last_name": "Steven Bart, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "MedImmune LLC", 
                "last_name": "Judith Falloon, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The following Solicited Symptoms will be recorded: Pain at the injection site; redness at the injection site; tenderness/soreness at the injection site; swelling at the injection site. Also assessed will be: Fever greater than/equal to 100.4F; headache; generalized muscle aches; fatigue or tiredness.", 
                "measure": "The occurence Solicited Symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (dosing) through Day 7"
            }, 
            {
                "description": "The proportion of subjects experiencing adverse events/serious adverse events from administration of IP through Day 28 post dosing.", 
                "measure": "The occurence of Adverse Events and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (dosing) through Day 28"
            }, 
            {
                "description": "The proportion of subjects experiencing SAEs, NOCDs, and AESIs from administration of IP through Day 360 post dosing.", 
                "measure": "The occurence of Serious Adverse Events, New Onset Chronic Disease (NOCDs) and Adverse Events of Special Interest (AESI)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (dosing) through Day 360"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115815"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Post-dose geometric mean titers (GMTs) and post dose geometric mean fold rises (GMFRs) from baseline in RSV A neutralizing antibody.", 
                "measure": "Humoral Immunity Assessments", 
                "safety_issue": "No", 
                "time_frame": "Days 29, 61, 91, 181, 271, and 361"
            }, 
            {
                "description": "Post dose geometric mean counts (GMCs) and GMFRs from baseline of RSV F peptide pool interferon (IFN) gamma ELISPOT responses.", 
                "measure": "Cellular immunity Assessments", 
                "safety_issue": "No", 
                "time_frame": "Days 8 and 29"
            }, 
            {
                "description": "Post dose seroresponse to RSV as measured by neutralizing antibody to RSV A.", 
                "measure": "Humoral Immunity Assessments", 
                "safety_issue": "No", 
                "time_frame": "Days 29, 61, 91, 181, 271, and 361"
            }, 
            {
                "description": "Post dose GMTs and GMFRs from baseline of anti-F immunoglobulin G antibodies.", 
                "measure": "Humoral Immunity Assessments", 
                "safety_issue": "No", 
                "time_frame": "Days 29, 61, 91, 181, 271, and 361"
            }, 
            {
                "description": "Post-dose seroresponse to RSV measured by anti-F IgG assay.", 
                "measure": "Humoral Immunity Assessments", 
                "safety_issue": "No", 
                "time_frame": "Days 29, 61, 91, 181, 271, and 361"
            }, 
            {
                "description": "Post dose cell-mediated immune response to RSV F measured by RSV F peptide pool IFN gamma ELISPOT assay.", 
                "measure": "Cellular immunity Assessments", 
                "safety_issue": "No", 
                "time_frame": "Days 8 and 29"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}